Avecho Biotechnology Ltd
ASX:AVE

Watchlist Manager
Avecho Biotechnology Ltd Logo
Avecho Biotechnology Ltd
ASX:AVE
Watchlist
Price: 0.01 AUD Market Closed
Market Cap: AU$36.7m

Net Margin

-262.4%
Current
Improving
by 229.2%
vs 3-y average of -491.6%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-262.4%
=
Net Income
AU$-3.6m
/
Revenue
AU$1.4m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-262.4%
=
Net Income
AU$-3.6m
/
Revenue
AU$1.4m

Peer Comparison

Country Company Market Cap Net
Margin
AU
Avecho Biotechnology Ltd
ASX:AVE
36.7m AUD
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
UK
Dechra Pharmaceuticals PLC
F:1PK
5.1B EUR
Loading...
US
Johnson & Johnson
NYSE:JNJ
529.7B USD
Loading...
CH
Roche Holding AG
SIX:ROG
275.3B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210.3B GBP
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
CH
Novartis AG
SIX:NOVN
221.9B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
269.1B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.8B USD
Loading...

Market Distribution

In line with most companies in Australia
Percentile
35th
Based on 4 004 companies
35th percentile
-262.4%
Low
-16 177 900% — -544.7%
Typical Range
-544.7% — 3.1%
High
3.1% — 3 174 540%
Distribution Statistics
Australia
Min -16 177 900%
30th Percentile -544.7%
Median -27.7%
70th Percentile 3.1%
Max 3 174 540%

Avecho Biotechnology Ltd
Glance View

Market Cap
36.7m AUD
Industry
Pharmaceuticals

Avecho Biotechnology Ltd. engages in the development, production, sale, and licensing of products incorporating its patented platform technology, Targeted Penetration Matrix (TPM), for the pharmaceutical, skin care and animal health and nutrition industries. The company is headquartered in Melbourne, Victoria. The firm's products pipeline includes Weaner Pig Starter TPM premix, Poultry TPM, Dairy TPM, and Veterinary Applications. The firm's segments include Production and Personal Care and Human Health. The Production and Personal Care segment manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches. The Human Health segment focuses on the development of patches, including TPM/Oxymorphone, TPM/enhanced, and TPM/Oxycodone. Its TPM products are commercialized under license Voveran TPM Gel, Instanac TPM Gel, Vital ET, and Ashland TPM.

AVE Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-262.4%
=
Net Income
AU$-3.6m
/
Revenue
AU$1.4m
What is Avecho Biotechnology Ltd's current Net Margin?

The current Net Margin for Avecho Biotechnology Ltd is -262.4%, which is above its 3-year median of -491.6%.

How has Net Margin changed over time?

Over the last 3 years, Avecho Biotechnology Ltd’s Net Margin has decreased from -191% to -262.4%. During this period, it reached a low of -1 026.9% on Jun 30, 2024 and a high of -191% on May 30, 2022.

Back to Top